Category: FDA & Regulatory Policy (Page 3)

November 22, 2016

ACT-AD Coalition Holds Ninth Annual Meeting

On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.
November 16, 2016

Experts Explore Federal Agency Collaborations to Close Alzheimer’s Disease Research Gaps at ACT-AD Coalition Annual Meeting

Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer’s disease research. 
October 31, 2016

An Update on 21st Century Cures

We provide an update on the 21st Century Cures Act, an important piece of legislation that the Alliance has been advocating for.
October 31, 2016

ACT-AD Will Host Ninth Annual Meeting

The ACT-AD Coalition will host its Ninth Annual FDA/Alzheimer's Disease Allies Meeting on November 16, 2016. 
August 30, 2016

Alliance Comments on the FDA’s Commitment Letter for PDUFA VI

In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.
August 23, 2016

Alliance Comments on PDUFA VI Commitment Letter

The Alliance provided comments in response to the U.S. Food and Drug Administration's PDUFA VI Commitment Letter.
August 18, 2016

Alliance’s Bens Presents at August PDUFA VI Public Meeting

The Alliance’s Vice President of Public Policy Cynthia Bens was invited by the U.S. Food and Drug Administration (FDA) to speak on two panels at an August 15 public meeting focused on the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA).
June 15, 2016

Alliance Offers Comments on FDA OTC Monograph User Fees

Last Friday, on June 10, Vice President of Public Policy Cynthia Bens presented comments on behalf of the Alliance at a U.S. Food and Drug Administration public meeting focused on OTC monograph user fees. 
June 10, 2016

OTC Monograph User Fee Public Meeting Remarks

These are remarks made by Alliance Vice President of Public Policy Cynthia Bens at the U.S. Food and Drug Administration's public meeting on OTC Monograph User Fees on June 10, 2016.
March 17, 2016

FY17 ACT-AD FDA Appropriations Request Letter

Letter to the House and Senate Appropriations Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies urging the Subcommittee to prioritize the U.S. Food and Drug Administration's (FDA) during Fiscal Year (FY) 2017 by increasing the agency's appropriated funding by $120 million.